Interestingly, the presence of CD19-negative subclones [58] or leukemic cells harboring exon 2 splicing variants [59] have also been observed in samples of patients with BCP-ALL at diagnosis, suggesting that the possible mechanisms of escape could be acquired even before exposure to the immunotherapies. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.